Table 3.
Drug combinations under investigation for SARS-CoV-2 infection (n=28 combinations)
| Registered trials, N | |
| Different antiviral combinations | 7 |
| Asc09f (Asc09/ritonavir)+oseltamivir | 1 |
| Darunavir/ritonavir+oseltamivir | 1 |
| Favipiravir+lopinavir/ritonavir | 1 |
| Lopinavir/ritonavir+oseltamivir | 1 |
| Lopinavir/ritonavir+emtritabine/tenofovir | 1 |
| Ritonavir+oseltamivir | 1 |
| Sofosbuvir+daclatasvir | 1 |
| Immunosuppressants combination | |
| Tocilizumab+adamumab | 1 |
| Antiviral+immunosuppressants | 2 |
| Favipiravir+tocilizumab | 2 |
| Antimalarials+antibacterial | 2 |
| Hydroxychloroquine+azithromycin | 2 |
| Antimalarials+antivirals | 10 |
| Darunavir/cobicistat+hydroxychloroquine | 1 |
| Darunavir/ritonavir+favipiravir+chloroquine | 1 |
| Darunavir/ritonavir+oseltamivir+chloroquine | 1 |
| Favipiravir+chloroquine | 2 |
| Hydroxychloroquine+lopinavir or atazanavir/ritonavir | 1 |
| Hydroxychloroquine+oseltamivir+lopinavir+interferon | 1 |
| Lopinavir/ritonavir+chloroquine | 1 |
| Lopinavir/ritonavir+hydroxychloroquine | 1 |
| Oseltamivir+chloroquine | 1 |
| Antivirals+interferon | 13 |
| Asc09/ritonavir+interferon | 1 |
| Favipiravir+interferon | 1 |
| Lopinavir/ritonavir+interferon | 6 |
| Ribavirin+interferon | 2 |
| Ribavirin+lopinavir/ritonavir+interferon | 1 |
| Umifenovir+interferon | 2 |
| Other combinations | 3 |
| Darunavir/cobicistat+thymosin | 1 |
| Lopinavir/ritonavir+thymosin | 1 |
| Ebastine+interferon+lopinavir | 1 |
Sources: WHO and ClinicalTrials.gov (as of 26 March 2020).
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.